How to Get Evenity (Romosozumab) in Georgia

Romosozumab-aqqg, marketed as Evenity, works as a monoclonal antibody by blocking sclerostin, a protein that typically prevents new bone from forming. The FDA has approved romosozumab for postmenopausal women with osteoporosis at high fracture risk, administered via subcutaneous injection of 210 mg (delivered as two 105 mg syringes) monthly for up to 12 months. Unlike bisphosphonates or denosumab, romosozumab cannot be compounded by 503A pharmacies since it is classified as a complex biologic product.

The practical barrier to getting Evenity in Georgia is rarely the drug's availability. It is prior authorization documentation and planning for what happens after the 12-dose course ends. The medication carries an FDA boxed warning against use within 12 months of a heart attack or stroke, requires a documented DXA-based diagnosis of osteoporosis, and is not covered by Georgia Medicaid for osteoporosis as of this writing. Patients who complete the course without a planned transition to an antiresorptive agent are at risk of rapid bone loss, a pattern well documented after stopping other bone-active therapies.

What romosozumab does and why access is complicated

Romosozumab has a dual action: it increases bone formation while decreasing bone resorption at the same time, a mechanism distinct from bisphosphonates or denosumab, which primarily slow bone breakdown. The FDA approved Evenity in April 2019 for postmenopausal women at high fracture risk, defined in the label as a history of osteoporotic fracture, multiple fracture risk factors, or failure of or intolerance to other osteoporosis therapies (FDA prescribing information).

A large randomized trial (ARCH) compared romosozumab followed by alendronate against alendronate alone and reported a substantial reduction in new vertebral fractures with the romosozumab-first sequence. The exact effect size cited in older summaries of this trial should be verified against the primary publication before being repeated as a precise number; we are not citing a specific percentage here because the identifier available to us could not be confirmed against the correct paper.

Osteoporosis is common nationally: the CDC reports that a substantial share of older US women have osteoporosis or low bone mass, based on national survey data (CDC osteoporosis FastStats). We did not find a verifiable, Georgia-specific fracture-rate comparison to the national average, so no state-level fracture statistic is asserted here. If a reader has seen a specific Georgia figure, it should be checked against state or CDC WONDER data directly rather than assumed from this page.

Who can prescribe Evenity in Georgia

Any Georgia-licensed physician (MD or DO) can prescribe romosozumab. Nurse practitioners and physician assistants can generally prescribe it under Georgia's collaborative or supervising-physician practice arrangements, though individual insurers sometimes require the supervising physician's NPI on the prior authorization form. This is a scope-of-practice generality, not a guarantee that a specific insurer will accept a specific prescriber type; confirm with the plan before scheduling.

Endocrinologists and rheumatologists write most Evenity prescriptions in practice because the prior authorization packet demands detailed fracture-risk documentation (DXA values, FRAX score, prior therapy history, cardiovascular clearance). We removed a claimed denial-rate comparison between primary care and specialist prescribers that appeared in an earlier draft of this page, because the only source offered for it was a homepage link that does not verifiably support that specific statistic. If a reader wants that comparison, it should come from a named, dated survey with methodology, not an unlinked claim.

Telehealth pathway for Georgia patients

Telehealth is a realistic way to start the Evenity evaluation process in Georgia. A typical sequence looks like this: an initial synchronous video visit, orders for labs and a DXA scan at a local imaging center, a follow-up visit to review results, prior authorization submission, and then scheduling of the first in-person injection.

Georgia has historically permitted prescribing of injectable biologics through telehealth without a preceding in-person exam, provided the visit meets the same standard of care as an office visit. Because telehealth prescribing rules and board guidance can change, the exact statutory citation and any conditions attached to it should be verified against the Georgia Composite Medical Board's current guidance before a patient or clinician relies on it. What is not in question is that the injection itself must still happen in person, at a clinic, infusion center, or through home health nursing, because romosozumab is not designed for patient self-injection in typical practice.

Patients in rural Georgia counties with limited endocrinology access may benefit most from this pathway, since it removes travel time to reach a subspecialist in Atlanta, Augusta, or Savannah for the initial workup, even though the injection appointment itself still requires an in-person visit.

Labs and screening required before prescribing

Romosozumab carries an FDA boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death (FDA label). The label states the drug should not be started in patients who have had a heart attack or stroke within the preceding year. Pre-prescribing workup generally includes:

Bone density assessment. A DXA scan is the basis for diagnosis. Many payers look for a T-score at or below -2.5 at the spine, femoral neck, or total hip, or a lower T-score combined with an elevated FRAX 10-year fracture probability, though exact thresholds are plan-specific and should be confirmed with the payer.

Cardiovascular screening. Blood pressure, cardiac history, and typically a lipid panel, documented specifically to rule out a myocardial infarction or stroke in the past 12 months, consistent with the boxed warning.

Metabolic labs. Serum calcium (corrected for albumin) and 25-hydroxyvitamin D are standard before starting, since hypocalcemia must be corrected first. Serum creatinine is also commonly checked.

Fracture history documentation. A vertebral fracture assessment on DXA or lateral spine imaging strengthens the prior authorization file when a vertebral fracture is present.

This is general prescribing and payer practice, not individualized dosing or diagnostic advice. A prescriber must determine candidacy for a specific patient.

Prior authorization in Georgia: what insurers typically ask for

Nearly every commercial and Medicare Advantage plan operating in Georgia requires prior authorization for Evenity. A typical documentation package includes the prior authorization form with diagnosis coding, the DXA report with T-scores, a FRAX score if available, documentation that there has been no MI or stroke in the past 12 months, and evidence of a prior bisphosphonate or denosumab trial or a documented contraindication (some plans waive this for patients with very low T-scores or prior fracture).

Medicare Part B covers Evenity as a physician-administered drug. Standard Part B cost-sharing (20% coinsurance after the deductible) applies unless the patient has supplemental coverage; specific coinsurance dollar amounts depend on the current Medicare Part B fee schedule and should be checked at the time of treatment rather than assumed from an older estimate.

Georgia Medicaid. As of this writing, Evenity is not listed on Georgia Medicaid's preferred drug list for osteoporosis; it appears only under a diabetes-related indication code in some formulary listings. Patients on Georgia Medicaid with severe osteoporosis who need romosozumab typically face an exception-request process. Coverage policy changes over time, so this should be reconfirmed directly with Peach State, CareSource, Amerigroup, or the current Georgia Medicaid preferred drug list before assuming coverage is unavailable.

Manufacturer copay assistance. Amgen has historically offered a copay assistance program for commercially insured patients that cannot be combined with Medicare or Medicaid. Program terms, maximum benefit amounts, and eligibility change periodically; current terms should be verified directly with the manufacturer's program rather than an older published figure.

Pharmacy and administration options in Georgia

Romosozumab is not typically self-injected by patients; the two syringes per dose are usually given by a clinician in the same visit. Specialty pharmacies (examples include the major national specialty pharmacy networks that serve Georgia) ship the refrigerated product to clinics, or the prescribing office may buy and bill the drug directly through Medicare Part B or a commercial medical benefit.

503A compounding pharmacies in Georgia, or anywhere else, cannot legally compound romosozumab. It is a complex monoclonal antibody, and compounding of biologics of this type is not part of standard 503A practice. Any offer of "compounded romosozumab" should be treated as a red flag and reported, not purchased.

Administration commonly happens at the prescribing physician's office, a hospital outpatient infusion center, or through a home health nursing visit, with cold-chain handling required up to the point of injection.

What the full course and cost picture looks like

The FDA label limits romosozumab to 12 monthly doses; repeat courses are not supported by the approved label or by the trial data behind the approval. After the course ends, patients are generally transitioned to an antiresorptive agent, most often a bisphosphonate or denosumab, to preserve the bone density gained during treatment. This transition principle is consistent with how the pivotal trial was designed (romosozumab followed by an antiresorptive), though the exact magnitude of benefit from that specific sequence should be checked against the primary trial publication before being quoted as a precise statistic.

There is a well-established pattern in the broader osteoporosis literature that stopping certain bone-active therapies (most clearly documented for denosumab) without a follow-up antiresorptive can lead to a rebound in bone turnover and vertebral fracture risk. Whether the same rebound magnitude applies after romosozumab discontinuation without follow-up therapy is a narrower question that a prescriber should discuss directly, rather than something this page can quantify from the sources at hand.

List price, coinsurance amounts, and manufacturer assistance caps for Evenity all change over time and were not something we could verify with confidence from a checkable primary source for this draft. Rather than repeat a specific dollar figure that cannot currently be confirmed, we recommend using the checklist below to get an accurate, current number for a specific patient's plan.

Evidence boundary: what is established, what is not

Established: Romosozumab is FDA-approved for postmenopausal women at high fracture risk, given monthly for up to 12 doses, with a boxed warning against use within 12 months of MI or stroke. It cannot be compounded. Georgia Medicaid does not currently cover it for osteoporosis.

Plausible but not confirmed by the sources available for this page: The precise magnitude of fracture-risk reduction from the pivotal trial, exact cost-effectiveness thresholds, and any Georgia-specific fracture-rate comparison to national averages. These claims may be true, but we could not verify the correct primary source for them in this draft, so we are not stating them as fact.

Not established: Any claim of a specific denial-rate difference between primary care and specialist prior authorization submissions in Georgia, and any specific current dollar coinsurance figure. These require a dated, checkable source before publication.

Verification checklist: stable facts vs. facts that change

Use this to separate what a reader can trust as durable from what must be reconfirmed before acting.

Stable, federal or clinical (safe to rely on without re-checking today):

• Evenity's FDA-approved indication (postmenopausal osteoporosis, high fracture risk)
• The boxed warning against starting romosozumab within 12 months of MI or stroke
• The 12-monthly-dose maximum on the FDA label
• The requirement for pre-treatment calcium and vitamin D correction
• The fact that 503A pharmacies cannot compound romosozumab

Date-sensitive, must be reconfirmed before a patient acts (as of the date you are reading this):

• Whether a specific Georgia commercial or Medicare Advantage plan requires prior bisphosphonate failure before approving Evenity
• Georgia Medicaid's current formulary status for Evenity (call the plan or check the current preferred drug list)
• Current Amgen copay assistance program terms and maximum benefit
• Current Medicare Part B coinsurance amount for the J-code covering romosozumab
• Which specific specialty pharmacies or local practices currently stock and bill Evenity in your area
• The exact Georgia telehealth statute or board guidance in effect, since board rules are periodically updated

How to use it: before scheduling a first visit, confirm the date-sensitive items directly with the prescriber's office, the specific insurance plan, and the specialty pharmacy. Do not rely on a cost or coverage figure found on any general reference page, including this one, without confirming it is current.

When to seek urgent care instead of waiting on this process

Chest pain, sudden weakness or numbness, slurred speech, or signs of a stroke or heart attack are emergencies regardless of osteoporosis treatment status; call 911 or go to an emergency department. A new fracture, severe new back pain, or inability to bear weight also warrants urgent evaluation rather than waiting for a scheduled osteoporosis follow-up.